Large Study Finds Lower Fracture Rates With Semaglutide Compared to Other Weight-Loss Medications
A population-based study published in *JAMA Internal Medicine* found that patients using semaglutide for weight loss had a lower risk of fractures compared to those taking other GLP-1 receptor agonists, addressing concerns about lean mass loss associated with these medications, according to the research led by Dr. Sarah Johnson and colleagues.
What the Study Found
The study analyzed data from over 120,000 adults with obesity who were prescribed GLP-1 receptor agonists between 2018 and 2022. Researchers tracked fracture incidence across different medications, including semaglutide, liraglutide, and dulaglutide. Results showed that semaglutide users had a 23% lower risk of fractures compared to those on other GLP-1 agonists, with no significant difference in lean mass loss between groups.
“This finding challenges the assumption that GLP-1 agonists uniformly increase fracture risk,” said Dr. Johnson, a researcher at the University of Michigan. “Semaglutide’s unique pharmacokinetic profile may contribute to this protective effect.”
How Semaglutide Differs
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, works by enhancing insulin secretion and slowing gastric emptying. Unlike other GLP-1 agonists, it has a longer half-life, allowing for once-weekly dosing. The study suggests its metabolic effects may indirectly support bone health by reducing inflammation and improving glucose control, though the exact mechanism remains under investigation.
“While the study does not establish causation, the correlation between semaglutide use and lower fractures is compelling,” said Dr. Michael Chen, an endocrinologist at the Cleveland Clinic, who was not involved in the research. “Patients and providers should consider this data when weighing treatment options.”
Implications for Patients
The findings are particularly relevant for individuals with obesity and osteoporosis, a condition affecting over 10 million Americans. Previous studies raised concerns about GLP-1 agonists’ potential to reduce lean mass, which could indirectly weaken bones. However, this study suggests that semaglutide’s impact on body composition may differ from other medications in the class.
“This study adds to a growing body of evidence that semaglutide may offer a safer profile for long-term weight management,” said Dr. Emily Rodriguez, a nutrition scientist at Harvard T.H. Chan School of Public Health. “However, individualized care remains critical, as patient-specific factors like diet and physical activity also influence bone health.”
What’s Next for Research?
While the study provides valuable insights, experts emphasize the need for longer-term trials to confirm these results. The research team plans to analyze data from additional cohorts to explore whether the observed effect is consistent across diverse populations.
“We’re also looking at how semaglutide interacts with other medications commonly used by patients with obesity, such as bisphosphonates,” Dr. Johnson said. “This will help clarify its role in comprehensive treatment strategies.”
FAQ
Why is this study significant for people using GLP-1 agonists?
The study addresses a key concern about bone health in patients using weight-loss medications. Semaglutide’s association with lower fracture rates suggests it may offer a safer alternative for some individuals, though further research is needed.
Are there other weight-loss medications with similar benefits?
The study specifically compared semaglutide to other GLP-1 agonists. While results for other medications like liraglutide or dulaglutide were not as favorable, the findings highlight the importance of individualized treatment plans.
What should patients do now?
Patients should discuss their options with healthcare providers, considering factors like medical history, lifestyle, and long-term goals. The study does not recommend changing medications without professional guidance.